30
Participants
Start Date
March 30, 2020
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Mogamulizumab
Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.
LD TSEBT
Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks
RECRUITING
Stanford Cancer Center, Stanford
Stanford University
OTHER